About Alacris Theranostics

Alacris Theranostics GmbH is a Berlin-based company specialising in the development of new approaches for personalised medicine for cancer patient diagnosis, treatment and drug stratification.
Alacris Theranostics applies a systems biology approach, designated ModCellTM, that was originally developed at the Max Planck Institute for Molecular Genetics by Prof. Lehrach’s research team and is exclusively licensed to Alacris Theranostics. Based on next-generation sequencing-derived genome and transcriptome information, kinetic pathway information, and mutation and drug databases, ModCellTM provides a ‘Virtual Patient’ model… read more

analytica alacris

Visit us at Analytica, Munich

April, 1 – 4 2014 Alacris Theranostics is present at the joint Berlin Brandenburg stand in Hall A3. At the


Virtual Patient Platform

Alacris Theranostics and the SAP Innovation Center are working closely together on new IT solutions for a virtual patient platform.


Alacris Theranostics: Partner of major study to uncover genetic key to treating bone diseases

Alacris Theranostics became a member of an international research project to analyse the genetic and molecular causes of bone diseases,


Alacris at Life Science Day 2013- 24.10.13

This year’s Life Science Day in Berlin-Dahlem on the 24.10.2013 takes place within the Berlin Health Week. In this anniversary


Alacris Theranostics Announces Illumina CSPro Certification for Next Generation Sequencing

Alacris Theranostics GmbH announced today that it has successfully completed Illumina CSPro™ certification for next generation sequencing (NGS); gaining entry


Alacris: Flagship Project for Berlin

As part of the series “Köpfe und Karrieren” (Heads and Careers) Berlin Regional Management Southwest (rmsw) portraits Alacris Theranostics GmbH


Tomorrow Today with Alacris Theranostics

Dr. Alexander Kühn, Head of Modeling, Alacris Theranostics GmbH, was invited for a studio discussion for the science magazine Tomorrow


Alacris Theranostics enters agreement with GSK to use ModCellTM System for early stage cancer research

Berlin, 14th November 2012 – Alacris Theranostics has entered into an agreement with GlaxoSmithKline (GSK) to apply Alacris’ proprietary ModCellTM


Alacris: One of the “most exciting German Biotech-Start-Ups”

German business journal “Wirtschaftswoche” considers the continuous upward trend of biotech start-ups in Germany, especially Alacris Theranostics as one of